- Court of Appeal—patent for antibodies from mice sufficiently disclosed (Regeneron Pharmaceuticals Inc v Kymab Ltd and another)
- What are the practical implications of the judgment?
- What was the background?
- What did the Court of Appeal decide?
- Infringement and construction
Intellectual Property analysis: In a case concerning the sufficiency of disclosure of a patent, the Court of Appeal allowed the appeal of the proprietor of two European patents for the production of human antibodies from transgenic mice, which the High Court had revoked on the ground that their specifications did not disclose the invention clearly enough and completely enough for it to be performed by a person skilled in the art.
Sign in or take a trial to read the full analysis.
To continue reading this news article, as well as thousands of others like it, sign in to LexisPSL or register for a free trial